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DOI 10.1016/j.ccr.2010.01.020SUMMARYThe somatic mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) observed in gliomas can lead to the
production of 2-hydroxyglutarate (2HG). Here, we report that tumor 2HG is elevated in a high percentage of
patients with cytogenetically normal acute myeloid leukemia (AML). Surprisingly, less than half of cases with
elevated 2HG possessed IDH1 mutations. The remaining cases with elevated 2HG had mutations in IDH2,
the mitochondrial homolog of IDH1. These data demonstrate that a shared feature of all cancer-associated
IDHmutations isproductionof theoncometabolite2HG.Furthermore,AMLpatientswith IDHmutationsdisplay
a significantly reducednumber of otherwell characterizedAML-associatedmutationsand/or associatedchro-
mosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.INTRODUCTION
Mutations in human cytosolic isocitrate dehydrogenase I (IDH1)
occur somatically in > 70% of grade II-III gliomas and secondary
glioblastomas, and in 8.5% of acute myeloid leukemias (AML)
(Mardis et al., 2009; Yan et al., 2009). Mutations have also
been reported in cancers of the colon and prostate (Kang
et al., 2009; Sjoblom et al., 2006). To date, all reported IDH1
mutations result in an amino acid substitution at a single arginine
residue in the enzyme’s active site, R132. A subset of interme-
diate grade gliomas lacking mutations in IDH1 has been found
to harbor mutations in IDH2, the mitochondrial homolog ofSignificance
Most cancer-associated enzyme mutations result in either ca
that the common feature of IDH1 and IDH2mutations observed
not shared by either wild-type enzyme. The product of this ne
samples, and we show that tumor metabolite analysis can id
this method, we discovered a 2HG-producing IDH2 mutation,
Overall, IDH1 and IDH2 mutations were observed in over 23%IDH1. The IDH2 mutations that have been identified in gliomas
occur at the analogous residue to IDH1 R132, IDH2 R172.
Both IDH1 R132 and IDH2 R172 mutants lack the wild-type
enzyme’s ability to convert isocitrate to a-ketoglutarate (Yan
et al., 2009). To date, all reported IDH1 or IDH2 mutations are
heterozygous, with the cancer cells retaining one wild-type
copy of the relevant IDH1 or IDH2 allele. No patient has been
reported with both an IDH1 and IDH2 mutation. These data argue
against the IDH mutations resulting in a simple loss of function.
Normally both cytosolic IDH1 and mitochondrial IDH2 exist as
homodimers within their respective cellular compartments, and
the mutant proteins retain the ability to bind to their respectivetalytic inactivation or constitutive activation. Here we report
in AML and glioma is the acquisition of an enzymatic activity
omorphic enzyme activity can be readily detected in tumor
entify patients with tumor-associated IDH mutations. Using
IDH2 R140Q, that was present in 9% of serial AML samples.
of AML patients.
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Figure 1. IDH1 R132 and IDH2 R172 Are
Analogous Residues that Both Interact
with the b-Carboxyl of Isocitrate
(A) Active site of crystallized human IDH1 with
isocitrate.
(B) Active site of human IDH2 with isocitrate,
modeled based on the highly homologous and
crystallized pig IDH2 structure. For (A) and (B),
carbon 6 of isocitrate containing the b-carboxyl
is highlighted in cyan, with remaining isocitrate
carbons shown in yellow. Carbon atoms of amino
acids (green), amines (blue), and oxygens (red)
are also shown. Hydrogen atoms are omitted
from the figure for clarity. Dashed lines depict
interactions < 3.1 A˚, corresponding to hydrogen
and ionic bonds. Residues coming from the other
monomer of the IDH dimer are denoted with
a prime (0) symbol.
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IDH1 can act as a dominant negative against wild-type IDH1
function, resulting in a decrease in cytosolic a-ketoglutarate
levels and leading to an indirect activation of the HIF-1a pathway
(Zhao et al., 2009). However, recent work has provided an alter-
native explanation. The R132H IDH1 mutation observed
in gliomas was found to display a gain of function for the
NADPH-dependent reduction of a-ketoglutarate to R(–)-2-
hydroxyglutarate (2HG) (Dang et al., 2009). This in vitro activity
was confirmed when 2HG was found to be elevated in IDH1-
mutated gliomas. Whether this neomorphic activity is a common
feature shared by IDH2 mutations was not determined.
IDH1 R132 mutations identical to those reported to produce
2HG in gliomas were recently reported in AML (Mardis et al.,
2009). These IDH1 R132 mutations were observed in 8.5% of
AML patients studied, and a significantly higher percentage of
mutation was observed in the subset of patients whose tumors
lacked cytogenetic abnormalities. IDH2 R172 mutations were
not observed in this study. However, during efforts to confirm
and extend these findings, we found an IDH2 R172K mutation
in an AML sample obtained from a 77-year-old woman. This
finding confirmed that both IDH1 and IDH2 mutations can occur
in AML and prompted us to more comprehensively investigate
the role of IDH2 in AML.
The present study was undertaken to see if IDH2 mutations
might share the same neomorphic activity as recently reported
for glioma-associated IDH1 R132 mutations. We also deter-
mined whether tumor-associated 2HG elevation could prospec-
tively identify AML patients with mutations in IDH. To investigate
the lack of reduction to homozygosity for either IDH1 or IDH2
mutations in tumor samples, the ability of wild-type IDH1 and/
or IDH2 to contribute to cell proliferation was examined.
RESULTS
IDH2 Is Mutated in AML
A recent study employing a whole-genome sequencing strategy
in an AML patient resulted in the identification of somatic IDH1
mutations in AML (Mardis et al., 2009). Based on the report
that IDH2 mutations were also observed in the other major tumor
type in which IDH1 mutations were implicated (Yan et al., 2009),
we sequenced the IDH2 gene in a set of de-identified AML DNA226 Cancer Cell 17, 225–234, March 16, 2010 ª2010 Elsevier Inc.samples. Several cases with IDH2 R172 mutations were identi-
fied. In the initial case, the IDH2 mutation found, R172K, was
the same mutation reported in glioma samples. It has been
recently reported that cancer-associated IDH1 R132 mutants
display a loss-of-function for the use of isocitrate as substrate,
with a concomitant gain-of-function for the reduction of a-keto-
glutarate to 2HG (Dang et al., 2009). This prompted us to deter-
mine if the recurrent R172K mutation in IDH2 observed in both
gliomas and leukemias might also display the same neomorphic
activity. In IDH1, the role of R132 in determining IDH1 enzymatic
activity is consistent with the stabilizing charge interaction of its
guanidinium moiety with the b-carboxyl group of isocitrate
(Figure 1A). This b-carboxyl is critical for IDH’s ability to catalyze
the interconversion of isocitrate and a-ketoglutarate, with the
overall reaction occurring in two steps through a b-carboxyl-
containing intermediate (Ehrlich and Colman, 1976). Proceeding
in the oxidative direction, this b-carboxyl remains on the sub-
strate throughout the IDH reaction until the final decarboxylating
step which produces a-ketoglutarate.
IDH1 R132 and IDH2 R172 Are Analogous Residues
that Both Interact with the b-Carboxyl of Isocitrate
To understand how R172 mutations in IDH2 might relate to the
R132 mutations in IDH1 characterized for gliomas, we modeled
human IDH2 based on the pig IDH2 structure containing
bound isocitrate (Ceccarelli et al., 2002). Human and pig IDH2
protein share over 97% identity and all active site residues
are identical. The active site of human IDH2 was structurally
aligned with human IDH1 (Figure 1). Similar to IDH1, in the active
site of IDH2 the isocitrate substrate is stabilized by multiple
charge interactions throughout the binding pocket. Moreover,
like R132 in IDH1, the analogous R172 in IDH2 is predicted to
interact strongly with the b-carboxyl of isocitrate. This raised
the possibility that cancer-associated IDH2 mutations at R172
might affect enzymatic interconversion of isocitrate and a-keto-
glutarate similarly to IDH1 mutations at R132.
Mutation of IDH2 R172K Enhances
a-Ketoglutarate-Dependent NADPH Consumption
To test whether cancer-associated IDH2 R172K mutations
shared the gain of function in a-ketoglutarate reduction
observed for IDH1 R132 mutations (Dang et al., 2009), we
Figure 2. Expression of R172K Mutant IDH2 Results in Enhanced
a-Ketoglutarate-Dependent Consumption of NADPH
(A) 293T cells transfected with wild-type or R172K mutant IDH2, or empty
vector, were lysed and subsequently assayed for their ability to generate
NADPH from NADP+ in the presence of 0.1 mM isocitrate.
(B) The same cell lysates described in (A) were assayed for their consumption
of NADPH in the presence of 0.5 mM a-ketoglutarate. Data for (A) and (B) are
each representative of three independent experiments. Data are presented
as the mean and standard error of the mean (SEM) from three independent
measurements at the indicated time points.
(C) Expression of wild-type and R172K mutant IDH2 was confirmed by western
blotting of the lysates assayed in (A) and (B). Reprobing of the same blot with
IDH1 antibody as a control is also shown.
Cancer Cell
IDH1 and IDH2 Mutations in AML Generate 2HGoverexpressed wild-type or R172K mutant IDH2 in cells with
endogenous wild-type IDH2 expression, and then assessed
isocitrate-dependent NADPH production and a-ketoglutarate-
dependent NADPH consumption in cell lysates. As reported
previously (Yan et al., 2009), extracts from cells expressing the
R172K mutant IDH2 did not display isocitrate-dependent
NADPH production above the levels observed in extracts from
vector-transfected cells. In contrast, extracts from cells express-
ing a comparable amount of wild-type IDH2 markedly increased
isocitrate-dependent NADPH production (Figure 2A). How-
ever, when these same extracts were tested for NADPH
consumption in the presence of a-ketoglutarate, R172K mutant
IDH2 expression was found to correlate with a significant
enhancement to a-ketoglutarate-dependent NADPH consump-
tion. Vector-transfected cell lysates did not demonstrate this
activity (Figure 2B). Although not nearly to the same degree as
with the mutant enzyme, wild-type IDH2 overexpression also
reproducibly enhanced a-ketoglutarate-dependent NADPH con-
sumption under these conditions.
Mutation of IDH2 R172K Results in Elevated 2HG Levels
R172K mutant IDH2 lacks the guanidinium moiety in residue
172 that normally stabilizes b-carboxyl addition in the intercon-
version of a-ketoglutarate and isocitrate. Yet R172K mutant
IDH2 exhibited enhanced a-ketoglutarate-dependent NADPH
consumption in cell lysates (Figure 2B). A similar enhancement
of a-ketoglutarate-dependent NADPH consumption has been
reported for R132 mutations in IDH1, resulting in conversion of
a-ketoglutarate to 2HG (Dang et al., 2009). To determine whether
cells expressing IDH2 R172K shared this property, we expressed
IDH2 wild-type or IDH2 R172K in cells. The accumulation of
organic acids, including 2HG, both within cells and in culture
medium of the transfectants was then assessed by gas-chroma-
tography mass spectrometry (GC-MS) after MTBSTFA derivati-
zation of the organic acid pool. We observed a metabolite peak
eluting at 32.5 min on GC-MS that was of minimal intensity in
the culture medium of IDH2-wild-type-expressing cells, but that
in the medium of IDH2-R172K-expressing cells had a markedly
higher intensity approximating that of the glutamate signal
(Figures 3A and 3B). Mass spectra of this metabolite peak fit
that predicted for MTBSTFA-derivatized 2HG, and the peak’s
identity as 2HG was additionally confirmed by matching its
mass spectra with that obtained by derivatization of commercial
2HG standards (Figure 3C). Similar results were obtained when
the intracellular organic acid pool was analyzed. IDH2 R172K
expressing cells were found to have an approximately 100-fold
increase in the intracellular levels of 2HG compared with the
levels detected in vector-transfected and IDH2-wild-type-over-
expressing cells (Figure 3D). Consistent with previous work,
IDH1-R132H-expressing cells analyzed in the same experiment
had comparable accumulation of 2HG in both cells and in culture
medium. 2HG accumulation was not observed in cells overex-
pressing IDH1 wild-type (data not shown).
Mutant IDH2 Produces the (R) Enantiomer of 2HG
Cancer-associated mutants of IDH1 produce the (R) enantiomer
of 2HG (Dang et al., 2009). To determine the chirality of the 2HG
produced by mutant IDH2 and to compare it with that produced
by R132H mutant IDH1, we used a two-step derivatizationmethod to distinguish the stereoisomers of 2HG by GC-MS: an
esterification step with R-()-2-butanolic HCl, followed by acet-
ylation of the 2-hydroxyl with acetic anhydride (Kamerling et al.,
1981). Test of this method on commercial S(+)-2HG and R()-
2HG standards demonstrated clear separation of the (S) and
(R) enantiomers, and mass spectra of the metabolite peaks
confirmed their identity as the O-acetylated di-()-2-butyl esters
of 2HG (see Figures S1A and S1B available online). By this
method, we confirmed the chirality of the 2HG found in cells
expressing either R132H mutant IDH1 or R172K mutant IDH2
corresponded exclusively to the (R) enantiomer (Figures S1C
and S1D).
Leukemic Cells Bearing Heterozygous R172K IDH2
Mutations Accumulate 2HG
To determine whether 2HG also accumulates in leukemic cells
with either IDH1 R132 or IDH2 R172 mutations, we next analyzed
the 2HG levels of selected leukemic samples. To date, every
IDH1 R132H or IDH2 R172K mutant AML sample has exhibitedCancer Cell 17, 225–234, March 16, 2010 ª2010 Elsevier Inc. 227
Figure 3. Expression of R172K Mutant IDH2
Elevates 2HG Levels within Cells and in
Culture Medium
(Aand B) 293Tcells transfectedwith IDH2wild-type
(A) or IDH2 R172K (B) were provided fresh culture
medium the day after transfection. Twenty-four
hours later, the medium was collected, from which
organic acids were extracted, purified, and derivat-
ized with MTBSTFA. Shown are representative gas
chromatographs for the derivatized organic acids
eluting between 30 to 34 min, including aspartate
(Asp) and glutamate (Glu). The arrows indicate the
expected elution time of 32.5 min for MTBSTFA-
derivatized 2HG, based on similar derivatization
of a commercial R(-)-2HG standard. Metabolite
abundance refers to GC-MS signal intensity.
(C) Mass spectrum of the metabolite peak eluting
at 32.5 min in (B), confirming its identity as
MTBSTFA-derivatized 2HG. The structure of this
derivative is shown in the inset, with the tert-butyl
dimethylsilyl groups added during derivatization
highlighted in green. m/e- indicates the mass (in
atomic mass units) to charge ratio for fragments
generated by electron impact ionization.
(D) Cells were transfected as in (A) and (B), and after
48 hr intracellular metabolites were extracted,
purified, MTBSTFA-derivatized, and analyzed by
GC-MS. Shown is the quantitation of 2HG signal
intensity relative to glutamate for a representative
experiment. See also Figure S1.
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intensity by GC-MS analysis that is R 30% of the intrasample
glutamate signal. In contrast, control extracts have either had
undetectable 2HG or a 2HG signal % 1% of that for glutamate
(n = 13, p < 0.001). Thus leukemic cells bearing either IDH1
R132 or IDH2 R172 mutation share the ability to accumulate
2HG in vivo with glioma cells exhibiting IDH1 R132 mutations.
IDH2 Is Critical for Proliferating Cells and Contributes
to the Conversion of a-Ketoglutarate into Citrate
in the Mitochondria
A peculiar feature of the IDH-mutated cancers described to date
is their lack of reduction to homozygosity. All tumors with IDH
mutations retain one IDH wild-type allele. To address this issue
we examined whether wild-type IDH1 and/or IDH2 might play
a role in either cell survival or proliferation. Consistent with this
possibility, we found that siRNA knockdown of either IDH1 or
IDH2cansignificantly reducetheproliferativecapacityofa cancer
cell line expressing both wild-type IDH1 and IDH2 (Figure 4A).
IDH1 is one of only three cytosolic enzymes that contribute to
the NADPH production required for nucleotide and lipid biosyn-
thesis during cell growth (DeBerardinis et al., 2007). In addition,
IDH1 contributes to the maintenance of cytosolic redox state
(Yan et al., 2009). Therefore, there are several reasons why
IDH1 might be important for cell proliferation. However, unlike
IDH1, IDH2 resides in the mitochondrial matrix. Mitochondria
normally contain a high level of NADPH and readily interconvert
NADH and NADPH (Rydstrom, 2006). Furthermore, it is IDH3, the
NAD+-dependent isocitrate dehydrogenase, that is believed to
be responsible for isocitrate conversion into a-ketoglutarate in
the mitochondrial citric acid cycle (McCormack and Denton,228 Cancer Cell 17, 225–234, March 16, 2010 ª2010 Elsevier Inc.1979). This raised the possibility that wild-type IDH2 might be
contributing to the ability of cancer cells to produce citrate
from glutamine, as illustrated in Figure 4B. Such an enzymatic
activity, though not ascribed to a particular IDH isoform, was
characterized in early metabolic studies (Ochoa, 1948; Siebert
et al., 1957). As shown in Figure 2B, when wild-type IDH2 was
overexpressed in cells, it was found to consume NADPH in an
a-ketoglutarate-dependent manner.
To test the possibility that wild-type IDH2 contributes to the
conversion of a-ketoglutarate into citrate in the mitochondria of
proliferating cells, we labeled cells with [13C-U]-L-glutamine
(glutamine +5), and subsequently measured isotopic enrichment
in citrate by GC-MS. Enrichment of citrate with five 13C atoms
(citrate +5) can arise from the reductive carboxylation of a-keto-
glutarate +5 to isocitrate +5, while citrate enriched with four 13C
atoms (citrate +4) can arise from oxidative metabolism of a-keto-
glutarate through the traditional citric acid cycle (Figure 4B). Both
forms of citrate production were reproducibly observed. To
examine the role of IDH2 in citrate production, cells were treated
with one of two independent IDH2 siRNAs. IDH2 siRNA-treated
cells displayed a significant reduction in levels of citrate +5, sup-
porting a role for mitochondrial IDH2 in reductive carboxylation.
Of note, no change in citrate +4 levels was observed, indicating
that the effect of IDH2 knockdown was specific and not affecting
other fundamental processes regulating the citric acid cycle
(Figure 4C). Similar labeling patterns were observed in aconitate,
an intermediate in the isomerization of isocitrate to citrate, with
aconitate +5 also reduced following IDH2 knockdown, and
aconitate +4 levels remaining unchanged (data not shown). In
contrast, when cells were treated with one of two independent
siRNAs against IDH3, there was a reproducible increase in
Figure 4. Both IDH1 and IDH2 Are Critical for Cell Proliferation
(A) SF188 cells were treated with either of two unique siRNA oligonucleotides
against IDH1 (siIDH1-A and siIDH1-B), either of two unique siRNA oligonucle-
otides against IDH2 (siIDH2-A and siIDH2-B), or control siRNA (siCTRL), and
total viable cells were counted 5 days later. Data are the mean ± SEM of
four independent experiments. In each case, both pairs of siIDH nucleotides
gave comparable results. A representative western blot from one of the exper-
iments, probed with antibody specific for either IDH1 or IDH2 as indicated, is
shown on the right-hand side.
(B) Model depicting the pathways for citrate +4 (blue) and citrate +5 (red)
formation in proliferating cells from [13C-U]-L-glutamine (glutamine +5).
(C) Cells were treated with two unique siRNA oligonucleotides against IDH2
or control siRNA, labeled with [13C-U]-L-glutamine, and then assessed for
isotopic enrichment in citrate by LC-MS. Citrate +5 and Citrate +4 refer to
citrate with five or four 13C-enriched atoms, respectively. Reduced expression
of IDH2 from the two unique oligonucleotides was confirmed by western blot.
Blotting with actin antibody is shown as a loading control.
(D) Cells were treated with two unique siRNA oligonucleotides against IDH3
(siIDH3-A and siIDH3-B) or control siRNA, and then labeled and assessed
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data support a role for IDH2 and not IDH3 in the conversion of
a-ketoglutarate into citrate by reductive carboxylation in the
mitochondria, and provide a possible explanation for the lack
of reduction to homozygosity for IDH2 mutations in cancer.
2HG Can Be Used as a Screening Test for Neomorphic
IDH Mutants
The above data suggest that the common feature of the IDH1
R132 and IDH2 R172 mutants is an ability to produce 2HG that
can be measured directly in tumor samples. This suggested that
screening for the presence of 2HG in tumor samples could be
used as an assay to detect IDH mutations. To test this hypothesis,
we obtained frozen samples of AML cells from 18 patients aged
50 years or older who presented with normal karyotype AML. All
18 samples were first screened for the intensity of their 2HG signal
on GC-MS as a percentage of the intrasample glutamate signal
(Table 1 and Figure 5). GC-MS analysis demonstrated that 9 of
18 samples had elevated 2HG. This fraction of samples was
much higher than expected from the reported incidence of IDH1
mutation (Mardis et al., 2009). To correlate the results with muta-
tion status, we sequenced IDH1 and IDH2 for all 18 samples in
a blinded fashion. All samples displaying a signal ratio for 2HG/
glutamate > 1% had either an IDH1 or IDH2 mutation. In contrast,
none of the samples with a 2HG/glutamate signal ratio% 1% had
an IDH mutation (Table 1). Thus in this sample set, 2HG measure-
ment was predictive of IDH mutation status.
The genetic analysis of these tumor samples revealed two
neomorphic IDH mutations that produce 2HG. Among the
IDH1 mutations, tumors with IDH1 R132C or IDH1 R132G accu-
mulated 2HG. This result is not unexpected, as a number of
mutations of R132 to other residues have also been shown to
accumulate 2HG in glioma samples (Dang et al., 2009).
The other neomorphic allele was unexpected. All five of the
IDH2 mutations producing 2HG in this sample set contained
the same mutation, R140Q. As shown in Figure 1, both R140 in
IDH2 and R100 in IDH1 are predicted to interact with the
b-carboxyl of isocitrate. Additional modeling revealed that
despite the reduced ability to bind isocitrate, the R140Q mutant
IDH2 is predicted to maintain its ability to bind and orient a-keto-
glutarate in the active site (Figure 6). This potentially explains the
ability of cells with this neomorph to accumulate 2HG in vivo.
As shown in Figure 5, samples containing IDH2 R140Q muta-
tions were found to have accumulated 2HG to levels 10-fold to
100-fold greater than the highest levels detected in IDH wild-
type samples.
IDH2Mutations AreMoreCommon Than IDH1Mutations
in AML
In the above sample set, just over half of the AML samples with
2HG accumulation had IDH2 mutations. This is in contrast to the
data reported for gliomas in which less than 5% of IDH mutations
were in IDH2 (Hartmann et al., 2009; Yan et al., 2009). Initialfor isotopic citrate enrichment by GC-MS. Shown are representative data
from three independent experiments. Reduced expression of IDH3 from the
two unique oligonucleotides was confirmed by western blot. In (C) and (D),
data are presented as mean and standard deviation of three replicates per
experimental group.
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Table 1. Patient Characteristics, Metabolite Analysis, and IDH
Status
Age (year) Sex 2HG/Glutamate IDH Mutation
50 M 0.01 None
54 M n.d. None
55 M n.d. None
57 F 1.94 IDH1 R132G
59 F n.d. None
60 M 0.01 None
61 M 0.11 IDH2 R140Q
62 M 0.47 IDH2 R140Q
65 M n.d. None
66 M 2.98 IDH1 R132C
68 M 0.61 IDH1 R132G
69 M n.d. None
69 F 1.38 IDH1 R132C
69 M 0.46 IDH2 R140Q
70 F 0.66 IDH2 R140Q
71 F n.d. None
72 F 0.32 IDH2 R140Q
78 M 0.01 None
Figure 5. Primary Human AML Sampleswith IDH1 or IDH2Mutations
Display Marked Elevations of 2HG
(A and B) AML patient peripheral blood, bone marrow, or pheresis samples
were extracted for analysis of intracellular metabolites. Organic acids were
purified, derivatized with MTBSTFA, and then analyzed by GC-MS as in
Figure 4. Shown are representative gas chromatograms from samples subse-
quently determined to lack IDH1 or IDH2 mutations (A) or to have a R140Q
mutation in IDH2 (B).
(C) 2HG signal intensity relative to the intrasample glutamate signal was quan-
tified in a total of 27 serial samples where adequate tumor tissue was available,
and then segregated by IDH mutation status. Horizontal bars depict the group
mean.
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tions in R172 (Mardis et al., 2009). In the 18 cases we examined
initially, all of the IDH2 mutations were IDH2 R140Q. However,
this sample may have been biased by either the sample size
and/or patient selection. We therefore analyzed 78 serial AML
samples collected from a single center to determine the
frequency of IDH1/2 mutation and investigated the coassocia-
tion of IDH1/2 mutations with other genes known to contribute
to AML pathogenesis (Table 2). Whereas IDH1 mutations were
found in 7.7% of samples in this analysis (6/78), twice as many
mutations were detected in IDH2, at a frequency of 15.4%
(12/78, p < 0.05). Both the R140Q and R172K neomorphic alleles
of IDH2 were identified. Of note, the IDH2 R140Q mutation
was observed in more patients (7/78) than the R172K allele of
IDH2 or R132 mutations in IDH1. None of the IDH2-mutated
samples were found to also have somatic mutations in Flt-3,
NPM1, or ASXL1. Furthermore, IDH2 and IDH1 mutations were
only observed in normal karyotype AML patients, whereas
known cytogenetic abnormalities were observed in 7 of 51
samples without IDH1/2 mutations (13.7%; all IDH mutants
versus IDH wild-type, p < 0.05). We also examined whether
IDH1 and/or IDH2 mutation status had any effect on the overall
survival of this set of patients. As was previously reported (Mar-
dis et al., 2009), mutations in IDH1 did not appear to affect overall
survival (p = 0.37, Figure S2A). However, we noted a trend
toward improved survival in patients who presented with IDH2
mutations (p = 0.08, Figure S2B).
DISCUSSION
Neomorphic Enzymatic Activity to Produce 2HG
Is the Shared Feature of IDH1 and IDH2 Mutations
Mutations in the cytosolic enzyme IDH1 have been reported in
a high percentage of gliomas and a significant subset of AML230 Cancer Cell 17, 225–234, March 16, 2010 ª2010 Elsevier Inc.patients (Mardis et al., 2009; Yan et al., 2009). Recently, IDH1
mutations of R132 were associated with the accumulation of
the metabolite 2HG in glial tumor samples (Dang et al., 2009).
The discovery of an elderly AML patient with an IDH2 R172 muta-
tion, the analogous residue to IDH1 R132, prompted us to test
whether this IDH2 mutation also resulted in a gain-of-function
ability to catalyze the conversion of a-ketoglutarate to 2HG.
In this study of IDH1 and IDH2 mutations in AML, we have
demonstrated that 2HG production is a common feature of the
spontaneous mutations in these two IDH homologs. By showing
that 2HG production can result from mutation at any of three resi-
dues that normally stabilize the b-carboxyl of isocitrate, IDH1
Figure 6. Structural Modeling of R140Q
Mutant IDH2
(A) Active site of human wild-type IDH2 with isoci-
trate replaced by a-ketoglutarate (a-KG). R140 is
well positioned to interact with the b-carboxyl
group that is added as a branch off carbon 3
when a-ketoglutarate is reductively carboxylated
to isocitrate.
(B) Active site of R140Q mutant IDH2 complexed
with a-ketoglutarate, demonstrating the loss of
proximity to the substrate in the R140Q mutant.
This eliminates the charge interaction from residue
140 that stabilizes the addition of the b-carboxyl
required to convert a-ketoglutarate to isocitrate.
Cancer Cell
IDH1 and IDH2 Mutations in AML Generate 2HGR132, IDH2 R172, and IDH2 R140, we demonstrate that it is the
truncated, noncarboxylating, reduction of a-ketoglutarate to
R()-2-hydroxyglutarate that is the common feature linking all
cancer-associated IDH mutations.
2HG as a Screening and Diagnostic Marker
With our demonstration that 2HG production is the common
feature of IDH1 and IDH2 mutations, the measurement of 2HG
levels allowed us to identify additional IDH mutations in AML
patients. This is exemplified in this study by the use of 2HG
screening to identify two distinct mutations in IDH2, R140Q
and R172K, that produce 2HG. These data demonstrate that at
least IDH2 neomorphic mutations are not limited to a single argi-
nine residue. Therefore, additional IDH1 and IDH2 neomorphic
alleles may still remain to be found in gliomas, hematopoietic
malignancies, and in other cancers. The 2HG levels in cancers
with IDH mutations are consistently 10-fold to 100-fold elevated
over levels found in samples lacking mutations of IDH1 or IDH2.
Inborn errors of metabolism that lead to 2HG elevation are
exceptionally rare and have devastating developmental conse-
quences (Kolker et al., 2002a). Tumors displaying elevated
2HG are unlikely to be false positives. Thus, 2HG appears to
be an important marker of IDH1/2-mutated neoplasms. Given
the quantities of 2HG that accumulate in the culture medium of
cells expressing IDH mutant enzymes, 2HG may even be detect-
able in the peripheral blood of leukemia patients with IDH muta-
tions at the time of presentation. We are currently testing the
potential of such a screening and diagnostic approach.Table 2. Clinical and Genetic Parameters of IDH1/2 Wild-Type and
IDH Status
Average Age at
Diagnosis (range)
Average Months
Survival (range)
# Complex
Cytogeneticsa
Wild-type (n = 60) 58.3 (6–86) 19.7 (1–70) 7/51 (13.7%)
IDH1 mutant (n = 6) 69.5 (51–91) 12.5 (2–20) 0/6 (0%)
IDH2 mutant
(R140Q n = 7;
R172K n = 5)
71.6 (48–85) 45.8 (4–107) 0/12 (0%)
All IDH
mutants (n = 18)
70.9 (48–91) 34.7 (2–107) 0/18 (0%)
See also Figure S2.
a Complex cytogenetics defined asR 3 cytogenetic abnormalities.
b Samples with alterations which could not be confirmed to be somatic wheMaintaining At Least One IDH1 and IDH2 Wild-Type
Allele May Be Essential for Transformed Cells
2HG production is a shared feature of heterozygous muta-
tions in either cytosolic IDH1 or mitochondrial IDH2. There is
a marked difference in the enzymatic rate of isocitrate-depen-
dent NADPH production by the wild-type proteins and a-keto-
glutarate-dependent NADPH consumption by both IDH1 and
IDH2 mutants (Figure 2 and Dang et al., 2009). Nevertheless,
both mutant proteins lead to an over 100-fold increase in tumor
2HG accumulation. In addition, it appears that both wild-type
IDH1 and IDH2 can play positive and nonredundant roles in
cell proliferation. The roles of IDH1 and IDH2 in supporting
cell proliferation are likely to be different. IDH1 contributes to
cytosolic NADPH production. In the case of IDH1 mutant
proteins, it has been reported that a local supply of NADPH
and a-ketoglutarate is required to drive 2HG production
(Dang et al., 2009). In the context of a wild-type/mutant IDH1
heterodimer, the required substrates for the mutant’s neomor-
phic activity are most readily provided by the wild-type
subunit’s normal activity on NADP+ and isocitrate. However,
for the neomorphic activity of mitochondrial IDH2 mutants,
the requirement for local generation of substrate is unlikely to
be absolute. Mitochondria typically have a high NADPH/
NADP+ ratio, supported in part by the ability to interconvert
NADPH and NADH in the matrix (Rydstrom, 2006). In addition,
mitochondrial a-ketoglutarate is maintained at high levels by
a variety of anaplerotic substrates. Although the exact role of
wild-type IDH2 in supporting cell growth will require furtherMutant AML Samples
(%)
# MLL
Rearrangement (%)
# Flt-3
Mutant (%)
# NPM1
Mutant (%)
# ASXL1
Mutant (%)b
4/60 (6.7%) 11/60 (18.3%) 4/60 (6.7%) 8/56 (14.3%)
0/6 (0%) 1/6 (16.7%) 1/6 (16.7%) 0/6 (0%)
2/12 (16.7%) 0/11 (0%) 0/9 (0%) 0/10 (0%)
2/18 (11.1%) 1/17 (5.9%) 1/15 (6.7%) 0/16 (0%)
re excluded from analysis.
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to contribute to the conversion of a-ketoglutarate into citrate via
a pathway of reductive carboxylation in the mitochondria of
proliferating cells.
2HG as an Oncometabolite
Although 2HG has been proposed to increase ROS levels in
patients with inborn errors of 2HG metabolism (Kolker et al.,
2002b; Latini et al., 2003), to date we have no evidence that the
metabolite acts as a mutagen. This is consistent with data
presented here that IDH1-mutated and IDH2-mutated AML
samples typically do not harbor other known mutations associ-
ated with AML, as well as a prior report that IDH-mutated gliomas
often lack other mutations that are commonly acquired early in
glioma pathogenesis (Yan et al., 2009). In an AML case with an
IDH1 mutation that was sequenced in its entirety (Mardis et al.,
2009), there were a relatively small total number of somatic, non-
synonymous mutations. However, a possibility by which 2HG
might contribute to tumorigenesis emerges from consideration
of the tumor subtypes in which IDH mutations are found with
high frequency: gliomas with mixed astrocytic and oligodendrog-
lial features, and acute myeloid leukemias. In both cases, prolif-
eration of a relatively undifferentiated cell population is central
to the disease, and pathogenesis is marked by a block to differ-
entiation rather than simply by an increase in proliferative rate.
Thus, one may speculate that 2HG’s effect in the tumor and its
microenvironment is to block cellular differentiation. Whether
cells carrying a mutant IDH transgene exhibit a block to differen-
tiation in vivo will need to be examined. The production of lineage-
specific mutant IDH transgenic animals or hematopoietic bone
marrow reconstitution following retroviral introduction of a mutant
IDH will allow future studies to test this hypothesis.
Whether 2HG fits into the broad class of mutagens or plays
a distinct role in carcinogenesis remains to be determined. For
now, it appears to represent a highly correlative maker for an
emerging class of somatic mutations in the isocitrate dehydroge-
nase enzymes. Importantly, these mutations appear to define
a significant subset of CNS tumors and leukemias. The identifi-
cation of frequent IDH2 mutations in AML increases the signifi-
cance of this family of mutations in understanding the pathogen-
esis of AML. Taken together, IDH mutations occur in 23% of
samples analyzed here. All IDH mutations reported to date share
the neomorphic ability to produce high levels of tumor 2HG.
Future studies are required to understand the role of 2HG in
leukemic transformation and to elucidate the role of IDH1/IDH2
in the pathogenesis of AML.
While preparing the final version of this paper, two cases of
IDH2 mutations were reported in leukemias that arose in patients
with myeloproliferative disease (Green and Beer, 2010). Thus,
IDH2 mutations can occur in both de novo cases of AML and
in AML arising secondary to myeloproliferative disorders.
EXPERIMENTAL PROCEDURES
Patient Selection and Statistical Analysis
Patient samples were obtained from either the Stem Cell and Xenotransplan-
tation Core Facility of the University of Pennsylvania or from the tissue collec-
tions of Memorial Sloan-Kettering Cancer Institute. Approval was obtained
from the institutional review boards at the University of Pennsylvania (IRB
protocol 703185) and Memorial Sloan Kettering Cancer Institute (IRB proto-232 Cancer Cell 17, 225–234, March 16, 2010 ª2010 Elsevier Inc.cols 95-091 and 06-107), and informed consent was provided according to
the Declaration of Helsinki. All samples were collected after de-identification
for these studies. For assessing clinical and genetic parameters of IDH1/2
wild-type and mutant AML, 78 serial samples from AML patients referred for
molecular testing at Memorial Sloan-Kettering Cancer Center were examined.
For 2HG assays, patient samples were obtained from the Stem Cell and
Xenotransplantation Core Facility of the University of Pennsylvania. The initial
18 samples were selected from de-identified AML patients aged 50 years or
older at diagnosis with lesions determined to have normal cytogenetic status.
Cells used for these assays were prepared by Ficoll separation of mononuclear
cells (MNCs) from peripheral blood or bone marrow. MNCs were frozen as
viable cells in 10% dimethyl sulfoxide. Student’s t test and chi-square analysis
were used for data analysis. A p value < 0.05 was considered significant.
Sequence Analysis of IDH1 and IDH2
Genomic DNA was extracted from bone marrow mononuclear cells or from
sorted leukemic cells; for samples with less than 70% blasts, flow cytometric
sorting (FACSAria) was used to isolate blast cells according to leukemic blast
immunophenotype before DNA isolation. High-throughput DNA sequence
analysis was used to screen for IDH1 and IDH2 mutations. All DNA samples
were whole genome amplified using Ø29 polymerase and mutations were
validated on unamplified DNA to ensure all mutations were present in the
diagnostic sample. Sequencing of IDH1 used primers which cover amino
acid residues 41-138 (sense, 50-TGTGTTGAGATGGACGCCTA-30; antisense,
50-GGTGTACTCAGAGCCTTCGC-30). Sequencing of IDH2 used primers
which cover amino acid residues 125-226 (sense, 50-CTGCCTCTTTGTGG
CCTAAG-30; antisense, 50-ATTCTGGTTGAAAGATGGCG-30). Sequence anal-
ysis was performed using Mutation Surveyor (SoftGenetics, State College PA)
and all mutations were validated by repeat polymerase chain reaction and
sequencing on unamplified DNA from the archival sample.
Structural Modeling
Human IDH2 has 97% homology with pig IDH2, and none of the 13 residues
that are different (out of 418 total, excluding the N-terminal mitochondrial
signal sequence) are found in the active site. A Protein Data Bank structure
of pig IDH2 is available, with isocitrate in the active site (1LWD) (Ceccarelli
et al., 2002). Based on the highly homologous pig structure, conservative
structural models of human IDH2 were built with the CHARMM molecular
mechanics package using the CHARMM27 force field. To model wild-type
IDH2 with isocitrate, the 13 residues of 1LWD differing between pig and human
were first changed to the human sequence. The side chains were then rebuilt,
hydrogen atoms added to all residues, the substrate, active site Mn2+ ions, and
conserved residues were restrained, and the structure minimized allowing
only the changed residues to relax. For the a-ketoglutarate complexes, the
substrate conformation/pose was first modeled on isocitrate by removing
the b-carboxyl group and replacing it with a hydrogen. The wild-type IDH2-
a-ketoglutarate complex was then minimized allowing only the active-site resi-
dues (as defined in entry 1LWD) and substrate to relax. The R140Q mutant
IDH2-a-ketoglutarate complex was subsequently modeled by changing argi-
nine 140 to glutamine, and rebuilding the side chain. The structure was then
minimized in two stages. First the mutated residue was allowed to relax, fol-
lowed by a second relaxation of the active site residues, Mn2+, and substrate.
All modeling images were generated using PyMOL Viewer (DeLano, 2002).
Constructing IDH1 and IDH2 Mutants
The cDNA clone of human IDH2 (BC009244) was purchased from Invitrogen
in pOTB7. Human IDH1 (BC012846.1) was purchased from ATCC in pCMV-
Sport6. Standard site-directed mutagenesis techniques were used to
generate IDH2 R172K by introducing a g515a change in the IDH2 open reading
frame (ORF). IDH1 R132H was made by introducing a g395a base pair change
in the IDH1 ORF. Wild-type and mutant sequences were then subcloned into
pcDNA3 (Invitrogen) and confirmed by direct sequencing before expression
in mammalian cells.
Cell Culture, Transfection, and Metabolic Labeling
293T cells and Bcl-xL-transfected SF188 cells (SF188) were cultured in DMEM
(Dulbecco’s modified Eagle’s medium; Invitrogen) with 10% fetal bovine
serum (CellGro). For expression of wild-type and mutant IDH1 and IDH2, cells
Cancer Cell
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facturer’s instructions. For IDH siRNA experiments, cells were transfected with
Lipofectamine RNAiMax, with oligonucleotides obtained from Sigma-Proligo.
For metabolic labeling experiments, cells were cultured in glutamine-free
DMEM supplemented with 4 mM [13C-U]-L-glutamine (Cambridge Isotope)
for the 3 hr prior to metabolite extraction.
Cell Lysate-Based Enzyme Assays
For IDH2 enzymatic assays, cells were lysed 48 hr following transfection, using
mammalian protein extraction reagent (Pierce) supplemented with protease
inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1 and 2 (Sigma).
Lysates were sonicated and centrifuged at 14,000 g at 4C. Supernatants were
then collected and normalized for total protein concentration. To measure IDH
oxidative activity, 0.3 mg of lysate protein was added to 200 ml of an assay
solution containing 100 mM Tris-HCl buffer (pH 7.5), 1.3 mM MnCl2,
0.33 mM EDTA, 0.1 mM b-NADP+, and 0.1 mM D-(+)-threo-isocitrate. The
increase in 340 nm absorbance (OD340) as a measure of NADPH production
was measured every 20 s for 30 min on a SpectraMax 190 spectrophotometer
(Molecular Devices). Data are plotted as the mean activity of three replicates
per lysate averaged among five time points centered at every 5 min. To
measure IDH reductive activity, 3 mg lysate protein was added to 200 ml of
an assay solution containing 100 mM Tris-HCl (pH 7.5), 1.3 mM MnCl2,
0.01 mM b-NADPH, and 0.5 mM a-ketoglutarate. NADPH consumption was
measured as the decrease in OD340, with three replicates per lysate. For all
experiments, OD340 changes in assay buffer lacking lysate protein were
measured and subsequently subtracted from the OD340 changes measured
in lysate replicates to arrive at final values.
Western Blot
For measurement of IDH2 levels in cell lysates used for enzymatic assays,
aliquots of the same lysates used in activity measurements were separated
by SDS-PAGE, transferred to nitrocellulose, probed with IDH2 mouse
monoclonal antibody (Abcam, ab55271), and then detected with horseradish
peroxidase-conjugated anti-mouse antibody (GE Healthcare, NA931V). For
assessing IDH knockdown in siRNA experiments, cells treated in parallel
with those used for labeling or proliferative studies were lysed 48 hr following
transfection in standard RIPA buffer (1% NaDOC, 0.1% SDS, 1% Triton X-100,
0.01 M Tris [pH 8.0], and 0.14 M NaCl) and then probed with IDH2 antibody as
described previously, IDH1 goat polyclonal antibody (Santa Cruz Biotech-
nology, sc49996), or IDH3A rabbit polyclonal antibody (Abcam, ab58641).
Actin antibody (Santa Cruz, sc1616) was also used for assessing equal protein
loading of western blots.
Metabolite Extraction
Cellular organic acids were extracted as previously described (Bennett et al.,
2008). Briefly, after gentle removal of culture medium from proliferating cells, or
freezing medium from frozen viable AML samples, cells were rapidly quenched
with 80% methanol, chilled to 80C, and then incubated at 80C for 15 min.
Extracts were subsequently transferred and centrifuged at 14,000 g for 20 min.
at 4C. The organic acid pool in the supernatant was further purified by drying
under nitrogen gas, redissolving in deionized water, and then elution from an
AG-1 X8 100-200 anion exchange resin (Bio-Rad) in 3 N HCl after washing
with five column volumes. For media analysis, culture medium from trans-
fected cells 24-48 hr following transfection was collected and diluted five-
fold with methanol. After centrifugation at 14,000 g for 20 min at 4C to remove
precipitated protein, supernatants were dried under nitrogen gas, and organic
acids were purified as described above.
GC-MS Analysis
After drying the HCl eluate, samples were redissolved in a 1:1 mixture of aceto-
nitrile and N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide (MTBSTFA;
Regis) and heated for 1 hr at 60C to derivatize prior to GC-MS analysis.
Samples were injected into an Agilent 7890A GC with an HP-5MS capillary
column, connected to an Agilent 5975C Mass selective detector operating
in splitless mode using electron impact ionization with ionizing voltage of
70 eV and electron multiplier set to 1060 V. GC temperature was started at
100C for 3 min, ramped to 230C at 4C/min and held for 4 min, then ramped
to 300C and held for 5 min. Mass range of 50-500 amu was recorded at2.71 scans/s. Isotopic enrichment in citric acid was monitored using ions at
m/e- 463 and 464 for citrate +4 and citrate +5 (containing 4 and 5 13C-enriched
atoms, respectively), formed through loss of a t-butyl (57 amu) and t-butyldi-
methylsilanol (132 amu) from the molecular ion tetra-TBDMS-citric acid
(648 amu). Isotopomer distributions were simultaneously corrected for natu-
rally occurring heavy isotopes of all elements in each mass fragment using
a correction matrix as previously described (Weckwerth, 2007). Identification
of the 2HG metabolite peak was confirmed using standards obtained from
Sigma. 2HG and glutamate signal intensities were quantified by integration
of peak areas.
Liquid-Chromatography Mass Spectrometry
Organic acids from cellular extracts were purified as described above,
followed by evaporation to dryness under nitrogen. After redissolving samples
in deionized water, citrate was detected on two different liquid chromatog-
raphy (LC) MS approaches, both of which gave comparable results. In both
cases, LC separation was by reversed phase chromatography using tributyl-
amine as an ion pairing agent (Lu et al., 2008; Luo et al., 2007) with ionization
by negative electrospray at 23 kV. The first MS approach used a Thermo
Discovery Max triple quadrupole mass spectrometer in multiple reaction
monitoring mode, with citrate quantified using the reaction 191 / 87 at
20 eV. Additional reactions for every possible labeled form of citrate were
also monitored using variations of the same transition. Reactions used to
monitor other TCA components have been described previously (Bajad
et al., 2006). The second MS approach used a Thermo Exactive Orbitrap
mass spectrometer operated at 100,000 mass resolving power, with citrate
and its isotope-labeled forms quantified based on extracted ion chromato-
grams at their exact masses.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2010.01.020.
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